Adamas Pharmaceuticals

Acquired

Supernus Pharmaceuticals | Innovating CNS Treatments

Emeryville, United States · Founded 2000 · $40.0M raised

Employees
51–200
Founded
2000
Business Model
B2B
Total Funding
$40.0M
Last Round
$40.0M Series DAug 2009
Rounds
2
Acquisition Date
Nov 2021

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 4 investors for this company. The full record is or through the API.

About

Adamas Pharmaceuticals was a specialty pharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) and neurological diseases. The company specialized in controlled-release combination therapeutics targeting conditions such as Parkinson's disease, multiple sclerosis, and other chronic CNS disorders. Adamas was headquartered in Emeryville, California, and traded on NASDAQ under the ticker ADMS. The company's mission was to improve the lives of patients suffering from CNS diseases through innovative treatments driven by integrity, commitment, and scientific innovation. In November 2021, Adamas was acquired by Supernus Pharmaceuticals for approximately $450 million, with its pipeline and products integrated into Supernus's broader CNS portfolio.

Summary

Adamas Pharmaceuticals is a Biotech company based in Emeryville, United States, founded in 2000. It has raised $40.0M in total across 2 rounds, most recently a $40.0M Series D round in Aug 2009. Investors include Aeris Capital, DAG Ventures and Mohr Davidow Ventures.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

AcquisitionAcquisition by Supernus PharmaceuticalsNov 2021

Sign up to see all 3 events

Funding: Series C through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Adamas Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/adamas-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/adamas-pharmaceuticals" alt="Adamas Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>